ReviewCurrent diabetes reports2014
Stem cell therapies in the management of diabetic retinopathy.
Review in Current diabetes reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- Progress and application of adipose-derived stem cells in the treatment of diabetes and its complications.Stem cell research & therapy · 2024Review
- Cell Replacement Therapy for Retinal and Optic Nerve Diseases: Cell Sources, Clinical Trials and Challenges.Pharmaceutics · 2021Review
- Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis.Neural regeneration research · 2021Article
- The Fate Status of Stem Cells in Diabetes and its Role in the Occurrence of Diabetic Complications.Frontiers in molecular biosciences · 2021Review
- Bone Marrow CD133Cell transplantation · 2018Article
- Diabetic corneal neuropathy: clinical perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.Frontiers in endocrinology · 2017Review
- Stem cell therapies in the treatment of diabetic retinopathy and keratopathy.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Diabetic Retinopathy: Animal Models, Therapies, and Perspectives.Journal of diabetes research · 2016Review
- Progenitor cell dysfunctions underlie some diabetic complications.The American journal of pathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy is the leading cause of blindness in the working population. We now understand that the pathogenesis of the disease contains both a neurodegenerative and vasodegenerative component. Yet despite this, current treatment is still limited to combating the proliferative end stage component of the disease rather than addressing its underlying causes. In recent years, much basic research has focused on demonstrating the potential that several classes of stem cells have in conferring both neuro- and vasoprotection on the diabetic retina. Further, progress has been made in using stem cells to stimulate both neuro and vascular regeneration. This review will discuss the current understanding as to what mechanisms underlie diabetic retinopathy while highlighting the types of stem cells which offer hope as potential novel therapies for diabetic retinopathy, including those that are now in clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.